Study Summary
Serosal cavity metastases of malignant tumor seriously affects the quality of life and survival time of patients with cancers in advanced stage. VEGFR1 is frequently expressed in breast cancer, ovarian cancer, lung cancer, gastric cancer and other malignant tumors and their metastases. The VEGFR1/PD-L1 dual-targeting CAR-T will be investigated in cancer patients with serosal cavity metastases.
Want to learn more about this trial?
Request More InfoInterventions
Dual-targeting VEGFR1 and PD-L1 CAR-T cellsBIOLOGICAL
In the dose escalation part, the dose levels will be escalated following a traditional escalation scheme for 3+3 design.
In the dose expansion part, patients will be assigned to different groups based on pleural or peritoneal metastases condition.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| West China Hospital, Sichuan University | Chengdu | Sichuan | China |